4 results match your criteria: "Irish Clinical Oncology Research Group (ICORG)[Affiliation]"
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
May 2024
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Article Synopsis
- The study examined the Breast Cancer Index (BCI) to predict benefits from extended endocrine therapy (EET) in hormone receptor-positive breast cancer patients participating in the NSABP B-42 trial.
- A total of 2,178 patients were analyzed, finding minimal overall RFI benefit from extended letrozole therapy, with no significant interaction between BCI levels and treatment outcome.
- However, after four years, patients with high BCI (H/I) showed significant benefits from EET, particularly in the HER2-negative subgroup, suggesting BCI's potential as a predictive marker for future studies.
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
J Natl Cancer Inst
November 2023
NRG Oncology SDMC, and the Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Background: The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)-based therapy. Seven-year results demonstrated a nonstatistically significant trend in disease-free survival (DFS) in favor of ELT. We present 10-year outcome results.
View Article and Find Full Text PDFUse of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
January 2019
NRG Oncology/NSABP, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Background: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer.
Methods: This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland.
Background: Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation.
View Article and Find Full Text PDF